Investing in science and generating new data and evidence to support our alternative tobacco and nicotine products are a priority at BAT. Sharing this evidence is essential for Tobacco Harm Reduction to be a reality and have maximum impact. We know that smokers need easy-to-understand information about the risks associated with smoking. They also need to know about the less risky* options that may be available to them, such as vapour, tobacco heating, and modern oral products. We are committed to carrying out scientific research and openly sharing the results so that consumers, regulators, and the Tobacco Harm Reduction community have access to reliable, relevant and robust evidence.
This innovative study demonstrates our commitment to researching the reduced-risk potential of our New Category products. What makes it particularly relevant and exciting is that the results generated are from people who have been using Vuse as they normally would for more than six months prior to testing.
Vuse: the number one global vaping brandi
Vuse is BAT’s flagship vapour brand and includes products such as ePod 2 and ePen 3. All Vuse products undergo thousands of hours of testing by scientists and R&D experts before they reach consumers.
This is the first real-world study to assess the impact of vaping with Vuse compared to smoking. The aim of the study was to show any differences in certain toxicants and indicators of potential harm related to several smoking-related diseases in people who have been using Vuse for at least six months compared to smokers, previous smokers, and people who have never smoked.
(ePod and ePen) for at least 6 months
who had been smoking for at least one year prior to screening
who had quit for at least six months
were included to act as a control group
The biomarkers assessed are important indicators that can be used to demonstrate:
- Biomarkers of Exposure: A person’s exposure to certain toxicants or chemicalsii
- Biomarkers of Potential Harm: Indicators of potential harm related to several smoking-related diseases, such as respiratory or cardiovascular diseaseiii
This study demonstrates BAT’s focus on science and innovation to deliver A Better TomorrowTM and reduce the health impact of the business. It assesses the potential of our reduced-risk* products to deliver a meaningful difference compared to smoking on important measures of exposure and early indicators of smoking-related disease.
The results of the study, which are currently being analysed, will be published later this year. It is hoped that the results will provide further supportive evidence that switching completely to Vuse could reduce relative risk for certain diseases among adult consumers compared to smoking, adding to the growing body of evidence on Vuse’s potential as a reduced-risk* product.
The results will provide important new insights and show us the differences between Vuse users, smokers and former smokers across a range of important biomarkers thought to be predictive of disease development. We look forward to sharing the data once available.